---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-105825"
form_type: "8-K"
ticker: "JAGX"
cik: "0001585608"
company_name: "Jaguar Health, Inc."
filed_at: "2025-04-30T23:59:59+00:00"
generated_at: "2026-05-23T02:20:05.800006+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Crofelemer reduces TPN up to 27% in MVID and 12.5% in SBS-IF in proof-of-concept trial

## Summary
- Initial POC data shows novel liquid crofelemer reduced parenteral support in MVID and SBS-IF patients by up to 27% and 12.5% respectively.
- Data presented at ELITE PED-GI Congress; stool volume/frequency reduced and urine output increased, indicating improved oral absorption.
- No approved drugs exist for MVID; crofelemer may qualify for EMA PRIME and FDA Breakthrough Therapy programs.
- Company supports three investigator-initiated trials and two placebo-controlled Phase 2 studies for MVID/SBS-IF globally.
- Additional POC results from IITs expected throughout 2025; early patient access possible in certain EU countries.

## SEC filing metadata
- accession: 0001193125-25-105825
- form_type: 8-K
- ticker: JAGX
- cik: 0001585608
- company_name: Jaguar Health, Inc.
- filed_at: 2025-04-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1585608/000119312525105825/0001193125-25-105825-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1585608/000119312525105825/d935544d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-105825
- JSON: https://secwatch.observer/filing/0001193125-25-105825.json
- Plain text: https://secwatch.observer/filing/0001193125-25-105825.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.